Karyopharm Therapeutics Inc. (KPTI) Operating income 2016–2025
Karyopharm Therapeutics Inc. (KPTI) annual operating income history from SEC filings — each fiscal year as reported.
-$90.7MFY2025 · since FY2016: -$110.7M → -$90.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$90.7M | +24.1% |
| FY2024 | -$119.4M | +7.8% |
| FY2023 | -$129.5M | +8.9% |
| FY2022 | -$142.2M | -44.7% |
| FY2021 | -$98.3M | +42.8% |
| FY2020 | -$171.8M | +9.2% |
| FY2019 | -$189.3M | -5.2% |
| FY2018 | -$179.9M | -37.8% |
| FY2017 | -$130.5M | -17.9% |
| FY2016 | -$110.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More KPTI financial trends
KPTI RevenueKPTI Net incomeKPTI Net marginKPTI Gross profitKPTI Gross marginKPTI Operating marginKPTI Operating cash flowKPTI Free cash flowKPTI Capital expendituresKPTI Return on equityKPTI Stock buybacksKPTI Dividends paidKPTI Total assetsKPTI Total liabilitiesKPTI Shareholders’ equityKPTI overview →